CASTOLDI GIOVANNA

Castoldi, G., Carletti, R., Barzaghi, F., Meani, M., Zatti, G., Perseghin, G., et al. (2024). Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models. PHARMACEUTICALS, 17(3) [10.3390/ph17030362]. Dettaglio

Castoldi, G., Carletti, R., Ippolito, S., Colzani, M., Pelucchi, S., Zerbini, G., et al. (2023). Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(13) [10.3390/ijms241310710]. Dettaglio

Castoldi, G., Carletti, R., Ippolito, S., Villa, I., Palmisano, B., Bolamperti, S., et al. (2022). Angiotensin II Modulates Calcium/Phosphate Excretion in Experimental Model of Hypertension: Focus on Bone. BIOMEDICINES, 10(11), 1-12 [10.3390/biomedicines10112928]. Dettaglio

Castoldi, G., Carletti, R., Ippolito, S., Stella, A., Zerbini, G., Pelucchi, S., et al. (2021). Angiotensin type 2 and mas receptor activation prevents myocardial fibrosis and hypertrophy through the reduction of inflammatory cell infiltration and local sympathetic activity in angiotensin ii‐dependent hypertension. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(24) [10.3390/ijms222413678]. Dettaglio

Castoldi, G., Carletti, R., Ippolito, S., Colzani, M., Barzaghi, F., Stella, A., et al. (2021). Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy. ACTA DIABETOLOGICA, 58(8), 1059-1070 [10.1007/s00592-021-01681-2]. Dettaglio